Such situations can be seen with the promising results of the combined utility of bevacizumab and erlotinib (epidermal growth factor receptor (EGFR)-TKI) for EGFR-mutant cancers, a combination which has been shown to lead to improvements in PFS for more than six months [68]. The gene discussed is EGFR; the disease is cancer.